| Using machine learning algorithms to predict immunotherapy response in patients with advanced melanoma P Johannet, N Coudray, DM Donnelly, G Jour, I Illa-Bochaca, Y Xia, ... Clinical Cancer Research 27 (1), 131-140, 2021 | 149 | 2021 |
| The ongoing racial disparities in melanoma: an analysis of the surveillance, epidemiology, and end results database (1975-2016) Y Qian, P Johannet, A Sawyers, J Yu, I Osman, J Zhong Journal of the American Academy of Dermatology 84 (6), 1585-1593, 2021 | 102 | 2021 |
| Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma JE Amengual, P Johannet, M Lombardo, K Zullo, D Hoehn, G Bhagat, ... Clinical Cancer Research 21 (20), 4663-4675, 2015 | 94 | 2015 |
| In search of our true selves: Feedback as a path to self-knowledge KL Bollich, PM Johannet, S Vazire Frontiers in psychology 2, 312, 2011 | 92 | 2011 |
| Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer P Johannet, A Sawyers, Y Qian, S Kozloff, N Gulati, D Donnelly, J Zhong, ... Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 76 | 2020 |
| Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma JE Amengual, S Clark-Garvey, M Kalac, L Scotto, E Marchi, E Neylon, ... Blood, The Journal of the American Society of Hematology 122 (12), 2104-2113, 2013 | 70 | 2013 |
| Melanoma prognosis: accuracy of the American Joint Committee on cancer staging manual eighth edition S Bajaj, D Donnelly, M Call, P Johannet, U Moran, D Polsky, R Shapiro, ... JNCI: Journal of the National Cancer Institute 112 (9), 921-928, 2020 | 54 | 2020 |
| Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade P Johannet, W Liu, D Fenyo, M Wind-Rotolo, M Krogsgaard, JM Mehnert, ... Clinical Cancer Research 28 (18), 4121-4130, 2022 | 28 | 2022 |
| Mechanisms of acquired drug resistance to the HDAC6 selective inhibitor ricolinostat reveals rational drug-drug combination with ibrutinib JE Amengual, SA Prabhu, M Lombardo, K Zullo, PM Johannet, ... Clinical Cancer Research 23 (12), 3084-3096, 2017 | 27 | 2017 |
| Optimization of an automated tumor-infiltrating lymphocyte algorithm for improved prognostication in primary melanoma M Chou, I Illa-Bochaca, B Minxi, F Darvishian, P Johannet, U Moran, ... Modern Pathology 34 (3), 562-571, 2021 | 23 | 2021 |
| Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors N Gulati, D Donnelly, Y Qian, U Moran, P Johannet, J Zhong, I Osman Journal of Translational Medicine 18, 1-6, 2020 | 21 | 2020 |
| Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors N Gulati, A Celen, P Johannet, JM Mehnert, J Weber, M Krogsgaard, ... Cancer medicine 10 (21), 7457-7465, 2021 | 15 | 2021 |
| Treatment with therapeutic anticoagulation is not associated with immunotherapy response in advanced cancer patients P Johannet, A Sawyers, N Gulati, D Donnelly, S Kozloff, Y Qian, ... Journal of Translational Medicine 19, 1-7, 2021 | 13 | 2021 |
| Clinical outcomes in cancer patients with COVID‐19 A Sawyers, M Chou, P Johannet, N Gulati, Y Qian, J Zhong, I Osman Cancer Reports 4 (6), e1413, 2021 | 10 | 2021 |
| Sirtuin och I-II deacetylas (DAC)-inhibering är synergistisk i prekliniska modeller och kliniska studier av lymfom JE Amengual, S Clark-Garvey, M Kalac, L Scotto, E Marchi, E Neylon, ... Blod 122 (12), 2104-13, 2013 | 7 | 2013 |
| Preliminary analysis of distinct clinical and biologic features of bone metastases in melanoma MA Wilson, J Zhong, P Johannet, Y Lee, N Masub, T Wechter, U Moran, ... Melanoma research 30 (5), 492-499, 2020 | 6 | 2020 |
| Radiological findings in pelvic solitary fibrous tumour P Johannet, A Kamaya, G Gayer BJR| case reports 2 (4), 20150373, 2016 | 6 | 2016 |
| Risk and tropism of central nervous system (CNS) metastases in patients with stage II and III cutaneous melanoma P Johannet, M Simons, Y Qian, N Azmy, JM Mehnert, JS Weber, J Zhong, ... Cancer 128 (20), 3620-3629, 2022 | 3 | 2022 |
| Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients. P Johannet, N Coudray, G Jour, DMA Donnelly, S Bajaj, U Moran, ... Journal of Clinical Oncology 37 (15_suppl), 2581-2581, 2019 | 3 | 2019 |
| The impact of germline alterations in appendiceal adenocarcinoma MB Foote, H Walch, Y Kemel, E Vakiani, P Johannet, M Sheehan, ... Clinical Cancer Research 29 (14), 2631-2637, 2023 | 2 | 2023 |
